Logo

SurroMed, Japanese Genomics Firm to Develop, Sell Biomarkers

Jul 31, 2003

NEW YORK, July 31 - SurroMed and Japanese genomics service company MediBic will co-develop biomarkers for drug discovery, the companies said today.

 

Terms of the deal also call for Tokyo-based MediBic to exclusively sell the biomarkers in Japan.

"We are confident that [MediBic's] ... record and their longstanding relationships will enable us to expand the market in Japan," said SurroMed CEO Gordon Ringold.

SurroMed's biomarker-discovery program pairs sample-preparation techniques with mass spectrometry. SurroMed then uses bioinformatics tools to analyze and mine the data.

MediBic has "relationships" with more than 20 Japanese pharmaceutical and biotechnology companies, according to the company.

Breaking News
The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.